Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXN | P10599 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596055 | 0.85 | — | — | |
| SCHEMBL22341497 | 0.79 | — | — | |
| SCHEMBL3503342 | 0.75 | TXN (0.55) | TXNTXNRD1ALDH1A1MEN1KMT2A | |
| SCHEMBL7064359 | 0.75 | — | — | |
| SCHEMBL31202896 | 0.72 | TXN (0.54) | TXNTXNRD1ALDH1A1CYP3A4FDPS | |
| SCHEMBL5551187 | 0.69 | TXN (0.51) | TXNTXNRD1ALDH1A1CYP3A4FDPS | |
| SCHEMBL4190883 | 0.68 | TAAR1 (0.47) | TXNTXNRD1ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL359998 | 0.67 | — | — | |
| SCHEMBL18321824 | 0.67 | TXN (0.49) | TXNTXNRD1CYP3A4FDPS | |
| SCHEMBL21331975 | 0.67 | TXN (0.49) | TXNTXNRD1CYP3A4FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4365189-A2 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2024-05-08 | — | — | EP | claimed |
| EP-4335863-A2 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | Genentech, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4245766-A9 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | Genentech, Inc. (US) | 2024-01-24 | — | — | EP | claimed |
| EP-4245766-A2 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | Genentech, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| EP-3654958-A1 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS | Triact Therapeutics, Inc. (US) | 2020-05-27 | — | — | EP | claimed |
| US-20200113852-A1 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS | TRIACT THERAPEUTICS, INC. | 2020-04-16 | — | — | US | claimed |
| WO-2020028616-A1 | METHODS FOR MANUFACTURING RECOMBINANT PROTEIN COMPRISING A DISULFIDE BOND | LONZA LTD (CH) | 2020-02-06 | — | — | WO | claimed |
| WO-2018237344-A1 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS | TRIACT THERAPEUTICS, INC. (US) | 2018-12-27 | — | — | WO | claimed |
| EP-3327026-A1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | Genentech, Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| EP-2188302-B1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH INC (US) | 2017-11-01 | — | — | EP | claimed |
| US-20140128575-A1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | claimed |
| EP-2586788-A1 | Prevention of disulfide bond reduction during recombinant production of polypeptides | Genentech, Inc. (US) | 2013-05-01 | — | — | EP | claimed |
| US-20130017598-A1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2013-01-17 | — | — | US | claimed |
| EP-2188302-A2 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | Genentech, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| US-20090053786-A1 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. | 2009-02-26 | — | — | US | claimed |
| WO-2009009523-A2 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| US-11999791-B2 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11987637-B1 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-1077249-A1 | Lubricating oil additive composition having a high friction coefficient at elevated temperatures | ORONITE JAPAN LIMITED (JP) | 2001-02-21 | — | — | EP | disclosed |
| WO-2000006088-A2 | INHIBITORS OF REDOX SIGNALING AND METHODS OF USING SAME | PROLX PHARMACEUTICALS, LP (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113852-A1 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS | PRDX3, PRDX6, PRDX1 | TXN 11/4885TXNRD1 9/4885ALDH1A1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.